Back Pain Device Maker Nevro Corp Raises $126 Million After IPO Tops Targets
Nevro, a startup waiting for approval of a device to treat back pain, raised $126 million in an IPO that priced higher than expected on Wednesday.
The Menlo Park company led by CEO Michael DeMane sold 7 million shares at $18, more than the 6.25 million shares it had projected and at a price that topped its announced range of between $15 and $17 a share.
The company was set to begin trading Thursday on the NYSE with the symbol of NVRO.
Help employers find you! Check out all the jobs and post your resume.
The Menlo Park company led by CEO Michael DeMane sold 7 million shares at $18, more than the 6.25 million shares it had projected and at a price that topped its announced range of between $15 and $17 a share.
The company was set to begin trading Thursday on the NYSE with the symbol of NVRO.
Help employers find you! Check out all the jobs and post your resume.